サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1433686

ペプチド・オリゴヌクレオチドCDMO市場規模、シェア、動向分析レポート：製品タイプ別、サービスタイプ別、最終用途別、地域別、セグメント別予測、2024年～2030年

Peptide And Oligonucleotide CDMO Market Size, Share & Trends Analysis Report By Product (Peptides, Oligonucleotides), By Service Type, By End Use (Pharmaceutical Companies, Biopharmaceutical Companies), By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 195 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ペプチド・オリゴヌクレオチドCDMO市場規模、シェア、動向分析レポート：製品タイプ別、サービスタイプ別、最終用途別、地域別、セグメント別予測、2024年～2030年
出版日: 2024年01月05日
発行: Grand View Research
ページ情報: 英文 195 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ペプチド・オリゴヌクレオチドCDMO市場の成長と動向：

Grand View Research社の最新レポートによると、世界のペプチド・オリゴヌクレオチドCDMO市場は2030年までに56億7,000万米ドルに達する見込みです。

2024年から2030年までのCAGRは12.5%です。ペプチドやオリゴヌクレオチドが様々な疾患に対する貴重な治療薬として認知されつつあることが、CDMOサービス需要を促進しています。また、ペプチドやオリゴヌクレオチド治療薬のパイプラインが増加していることや、この分野でのCDMOの浸透が進んでいることも、市場の成長を促す要因のひとつとなっています。

市場は断片化されており、複数企業が同様技術力と加工能力を有しています。これら企業は、ペプチドやオリゴヌクレオチド開発、データ解釈、サンプル分析、臨床試験サポートに関する様々なサービスを提供しています。同市場は、品質保証、技術進歩、規制へ対応、高価値で多様なサービスを提供する能力といった要因による熾烈な競争が特徴です。

ペプチドやオリゴヌクレオチドをベースとした治療薬の開発・製造に対する大手企業による投資の拡大は、市場の成長を支える顕著な要因の1つです。例えば、2023年9月、CordenPharma社は、CordenPharma Colorado社の設備増強による商業用ペプチド生産能力の拡大を発表し、現在、世界最大の固相ペプチド合成（SPPS）製造施設となっています。さらに、2023年9月、CombiGeneはAmbioPharmをZyneyroも関与するペプチドベースの疼痛プロジェクトCOZY01のCDMOパートナーに選びました。

COVID-19のパンデミックは市場に中程度の影響を与えました。COVID-19パンデミックの初期段階は、渡航制限、サプライチェーンの混乱、臨床試験の後退などの結果、臨床試験に顕著な影響を与えました。それにもかかわらず、抗ウイルスペプチドが重視されるようになり、mRNAワクチンが迅速に開発されるようになっています。さらに、ペプチドベース治療薬生産を促進する目的で、バイオ医薬品企業間協力や提携が大幅に増加しています。

ペプチド・オリゴヌクレオチドCDMO市場レポート・ハイライト

  • このセグメントは、ペプチドベースの治療薬に対する需要の高まりと、ペプチドの使用を伴う臨床試験数の増加が牽引しています。
  • サービスタイプ別では、受託製造セグメントが2023年に65.0%最大シェアを占めました。このセグメントの大幅な市場シェアは、主に製造委託費用対効果に後押し製造委託サービス需要拡大に起因します。
  • バイオ医薬品企業は、ペプチドベースの医薬品の研究開発に注力するバイオ医薬品企業の増加により、分析期間を通じて13.0%のCAGRを記録すると予測されます。
  • アジア太平洋地域は、予測期間中に13.4%という最も高いCAGRを記録すると予測されています。この大幅な成長は、主に欧米の製薬会社が中国やインドなどの新興国に製造業務をアウトソーシングする傾向が高まっていることに起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ペプチド・オリゴヌクレオチドCDMO市場変数、動向および範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ペプチド・オリゴヌクレオチドCDMO市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19感染症の影響分析

第4章 ペプチド・オリゴヌクレオチドCDMO市場：製品推定・動向分析

  • ペプチド・オリゴヌクレオチドCDMO市場、製品別：セグメントダッシュボード
  • ペプチド・オリゴヌクレオチドCDMO市場、製品別：変動分析

第5章 ペプチド・オリゴヌクレオチドCDMO市場：サービスタイプの推定・動向分析

  • ペプチド・オリゴヌクレオチドCDMO市場、サービスタイプ別：セグメントダッシュボード
  • ペプチド・オリゴヌクレオチドCDMO市場、サービスタイプ別：変動分析

第6章 ペプチド・オリゴヌクレオチドCDMO市場：最終用途の推定・動向分析

  • ペプチド・オリゴヌクレオチドCDMO市場、最終用途別：セグメントダッシュボード
  • ペプチド・オリゴヌクレオチドCDMO市場、最終用途別：変動分析

第7章 ペプチド・オリゴヌクレオチドCDMO市場：地域推定・動向分析

  • 地域市場シェア分析、2023年および2030年
  • 地域市場ダッシュボード
  • 世界の地域市場のスナップショット
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • インド
    • 中国
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 市場参入企業の分類
    • イノベーター
    • マーケットリーダー
    • 新興プレイヤー
    • 企業の市場シェア分析、2023年
  • 企業プロファイル
    • PolyPeptide Group
    • STA Pharmaceutical Co. Ltd.
    • Bachem
    • Creative Peptides
    • Aurigene Pharmaceutical Services Ltd
    • Merck KGaA
    • EUROAPI
    • Curia Global, Inc.
    • CordenPharm
    • Sylentis, SA
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 North America Peptide and Oligonucleotide CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 5 North America Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 6 North America Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 7 U.S. Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 9 U.S. Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 10 Canada Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 11 Canada Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 12 Canada Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Europe Peptide and Oligonucleotide CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 14 Europe Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 15 Europe Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 16 Europe Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 17 U.K. Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 18 U.K. Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 19 U.K. Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Germany Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 22 Germany Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 23 France Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 24 France Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 25 France Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 Italy Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 27 Italy Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 28 Italy Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 29 Spain Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 30 Spain Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 31 Spain Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 32 Denmark Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 33 Denmark Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 34 Denmark Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Sweden Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 36 Sweden Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 37 Sweden Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 38 Norway Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 39 Norway Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 40 Norway Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Peptide and Oligonucleotide CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 45 China Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 46 China Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 47 China Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 48 Japan Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 49 Japan Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 50 Japan Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 51 India Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 52 India Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 53 India Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Australia Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 55 Australia Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 56 Australia Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 57 South Korea Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 59 South Korea Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 60 Thailand Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 61 Thailand Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 62 Thailand Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 Latin America Peptide and Oligonucleotide CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 64 Latin America Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 65 Latin America Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 66 Latin America Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 67 Brazil Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 68 Brazil Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 69 Brazil Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 70 Mexico Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 71 Mexico Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 72 Mexico Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 73 Argentina Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 74 Argentina Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 75 Argentina Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa Peptide and Oligonucleotide CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 79 Middle East and Africa Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 80 South Africa Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 81 South Africa Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 82 South Africa Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 86 UAE Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 87 UAE Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 88 UAE Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 91 Kuwait Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modelling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Primary research pattern
  • Fig. 8 Primary interviews in North America
  • Fig. 9 Primary interviews in Europe
  • Fig. 10 Primary interviews in Asia Pacific
  • Fig. 11 Primary interviews in Latin America
  • Fig. 12 Primary interviews in MEA
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Segment Snapshot
  • Fig. 16 Competitive Landscape Snapshot
  • Fig. 17 Peptide and Oligonucleotide CDMO market segmentation
  • Fig. 18 Parent market outlook (2023)
  • Fig. 19 Related/ancillary market outlook (2023)
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Market restraint relevance analysis (Current & future impact)
  • Fig. 22 Porter's five forces analysis
  • Fig. 23 SWOT analysis, by a factor (political & legal, economic and technological)
  • Fig. 24 Peptide and Oligonucleotide CDMO Market Product outlook: Segment dashboard
  • Fig. 25 Peptide and Oligonucleotide CDMO :Product movement analysis
  • Fig. 26 Peptides market, 2018 - 2030 (USD Million)
  • Fig. 27 Oligonucleotides market, 2018 - 2030 (USD Million)
  • Fig. 28 Peptide and Oligonucleotide CDMO Market Service Type outlook: Segment dashboard
  • Fig. 29 Peptide and Oligonucleotide CDMO : Service Type type movement analysis
  • Fig. 30 Contract Development market, 2018 - 2030 (USD Million)
  • Fig. 31 Contract Manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 32 Peptide and Oligonucleotide CDMO market End Use outlook: Segment dashboard
  • Fig. 33 Peptide and Oligonucleotide CDMO market: End Use movement analysis
  • Fig. 34 Pharmaceutical Companies market, 2018 - 2030 (USD Million)
  • Fig. 35 Biopharmaceutical Companies market, 2018 - 2030 (USD Million)
  • Fig. 36 Others market, 2018 - 2030 (USD Million)
  • Fig. 37 Regional marketplace: Segment dashboard
  • Fig. 38 Regional outlook, 2023 & 2030
  • Fig. 39 North America market, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 41 Canada market, 2018 - 2030 (USD Million)
  • Fig. 42 Europe market, 2018 - 2030 (USD Million)
  • Fig. 43 Germany market, 2018 - 2030 (USD Million)
  • Fig. 44 UK market, 2018 - 2030 (USD Million)
  • Fig. 45 France market, 2018 - 2030 (USD Million)
  • Fig. 46 Italy market, 2018 - 2030 (USD Million)
  • Fig. 47 Spain market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark market, 2018 - 2030(USD Million)
  • Fig. 49 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 50 Norway market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 52 China market, 2018 - 2030 (USD Million)
  • Fig. 53 Japan market, 2018 - 2030 (USD Million)
  • Fig. 54 India market, 2018 - 2030 (USD Million)
  • Fig. 55 Australia market, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 57 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 58 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 59 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 60 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 61 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 62 Middle East & Africa market, 2018 - 2030 (USD Million)
  • Fig. 63 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 64 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 65 UAE market, 2018 - 2030 (USD Million)
  • Fig. 66 Kuwait market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-182-4

Peptide And Oligonucleotide CDMO Market Growth & Trends:

The global peptide and oligonucleotide CDMO market is expected to reach USD 5.67 billion by 2030, according to a new report by Grand View Research, Inc. , registering a CAGR of 12.5% from 2024 to 2030. The growing recognition of peptides and oligonucleotides as valuable therapeutic agents for various diseases is fueling the demand for CDMO services. Moreover, the increasing pipeline of peptides and oligonucleotide therapeutics and the growing penetration of CDMOs in the field are a few of the factors driving the growth of the market.

The market is fragmented, with several players having similar technological and processing capabilities. These companies offer various services related to peptide and oligonucleotide development, data interpretation, sample analysis, and clinical trial support. The market is characterized by fierce competition driven by factors such as quality assurance, technological advancements, regulatory compliance, and the ability to offer high-value and diverse services.

The growing investment by major companies in the development and manufacturing of peptides and oligonucleotide-based therapeutics is one of the prominent factors supporting the growth of the market. For instance, in September 2023, CordenPharma announced the expansion of its commercial peptide production capabilities through the enhancement of facilities at CordenPharma Colorado, which now stands as the world's largest Solid-Phase Peptide Synthesis (SPPS) manufacturing facility. Additionally, in September 2023, CombiGene selected AmbioPharm as the CDMO partner for their peptide-based pain project, COZY01, which also involves Zyneyro.

The COVID-19 pandemic moderately impacted the market. The early stages of the COVID-19 pandemic had a notable impact on clinical trials, as a result of travel restrictions, disruptions in the supply chain, and setbacks in clinical trials. Nonetheless, it also presented prospects, notably the heightened emphasis on antiviral peptides and the swift creation of mRNA vaccines. Furthermore, there has been a substantial increase in collaborations and partnerships across biopharmaceutical companies with an aim to boost the production of peptide-based therapeutics.

Peptide And Oligonucleotide CDMO Market Report Highlights:

  • The peptides segment accounted for the largest share of 66.3% in 2023.The segment is driven by the growing demand for peptide-based therapeutics and the rise in the number of clinical trials involving the use of peptides.
  • Based on the service type, the contract manufacturing segment accounted for the largest share of 65.0% in 2023. The substantial market share in this segment primarily results from the growing demand for outsourced manufacturing services, driven by the cost-effectiveness of outsourced manufacturing.
  • Biopharmaceutical companies are anticipated to witness the highest CAGR of 13.0% across the analysis timeframe due to the increasing number of biopharmaceutical companies focusing on research and development of peptide-based drugs.
  • Asia Pacific is anticipated to witness the highest CAGR of 13.4% during the forecast time frame. The substantial growth is primarily attributed to the rising trend of Western pharmaceutical companies outsourcing their manufacturing operations to emerging economies like China and India.

Table of contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Product
    • 1.1.3. Service Type
    • 1.1.4. End Use
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Peptide and Oligonucleotide CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing therapeutic applications of peptides and oligonucleotides
      • 3.2.1.2. Advances in peptide synthesis, delivery methods, and gene-editing technologies have expanded the possibilities for developing innovative therapies
      • 3.2.1.3. Growing research and development investments
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Complexities associated with clinical trial studies
      • 3.2.2.2. Challenges related to quality control
  • 3.3. Peptide and Oligonucleotide CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat Of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Peptide and Oligonucleotide CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Peptide and Oligonucleotide CDMO Market, By Product: Segment Dashboard
  • 4.2. Peptide and Oligonucleotide CDMO Market, By Product: Movement Analysis
  • 4.3. Peptide and Oligonucleotide CDMO Market Estimates & Forecasts, By Product, 2018 - 2030
    • 4.3.1. Peptides
      • 4.3.1.1. Peptides Clinical Phase Outsourcing Services Market, 2018 to 2030, (USD Million)
    • 4.3.2. Oligonucleotides
      • 4.3.2.1. Oligonucleotides Clinical Phase Outsourcing Services Market, 2018 to 2030, (USD Million)

Chapter 5. Peptide and Oligonucleotide CDMO Market: Service Type Estimates & Trend Analysis

  • 5.1. Peptide and Oligonucleotide CDMO Market, By Service Type: Segment Dashboard
  • 5.2. Peptide and Oligonucleotide CDMO Market, By Service Type: Movement Analysis
  • 5.3. Peptide and Oligonucleotide CDMO Market Estimates & Forecasts, By Service Type, 2018 - 2030
    • 5.3.1. Contract Development
      • 5.3.1.1. Contract Development Peptide and Oligonucleotide CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.2. Contract Manufacturing
      • 5.3.2.1. Contract Manufacturing Peptide and Oligonucleotide CDMO Market, 2018 to 2030, (USD Million)

Chapter 6. Peptide and Oligonucleotide CDMO Market: End Use Estimates & Trend Analysis

  • 6.1. Peptide and Oligonucleotide CDMO Market, By End Use: Segment Dashboard
  • 6.2. Peptide and Oligonucleotide CDMO Market, By End Use: Movement Analysis
  • 6.3. Peptide and Oligonucleotide CDMO Market Estimates & Forecasts, By End Use, 2018 - 2030
    • 6.3.1. Pharmaceutical Companies
      • 6.3.1.1. Pharmaceutical Companies Peptide and Oligonucleotide CDMO Market 2018 to 2030 (USD Million)
    • 6.3.2. Biopharmaceutical Companies
      • 6.3.2.1. Biopharmaceutical Companies Peptide and Oligonucleotide CDMO Market 2018 to 2030 (USD Million)
    • 6.3.3. Others
      • 6.3.3.1. Others Peptide and Oligonucleotide CDMO Market 2018 to 2030 (USD Million)

Chapter 7. Peptide and Oligonucleotide CDMO Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Competitive Scenario
      • 7.5.1.3. Regulatory Framework
      • 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 7.5.2. Germany
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 7.5.3. France
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 7.5.4. Italy
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 7.5.5. Spain
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 7.5.6. Denmark
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 7.5.7. Sweden
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 7.5.8. Norway
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Competitive Scenario
      • 7.6.1.3. Regulatory Framework
      • 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 7.6.2. India
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 7.6.4. South Korea
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 7.6.6. Thailand
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Competitive Scenario
      • 7.7.1.3. Regulatory Framework
      • 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 7.7.2. Mexico
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key Country Dynamics
      • 7.8.1.2. Competitive Scenario
      • 7.8.1.3. Regulatory Framework
      • 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 7.8.3. UAE
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 7.8.4. Kuwait
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2023
  • 8.2. Company Profiles
    • 8.2.1. PolyPeptide Group
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Performance
      • 8.2.1.3. Service Benchmarking
      • 8.2.1.4. Strategic Initiatives
    • 8.2.2. STA Pharmaceutical Co. Ltd.
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Financial Performance
      • 8.2.2.3. Service Benchmarking
      • 8.2.2.4. Strategic Initiatives
    • 8.2.3. Bachem
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Financial Performance
      • 8.2.3.3. Service Benchmarking
      • 8.2.3.4. Strategic Initiatives
    • 8.2.4. Creative Peptides
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Financial Performance
      • 8.2.4.3. Service Benchmarking
      • 8.2.4.4. Strategic Initiatives
    • 8.2.5. Aurigene Pharmaceutical Services Ltd
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Financial Performance
      • 8.2.5.3. Service Benchmarking
      • 8.2.5.4. Strategic Initiatives
    • 8.2.6. Merck KGaA
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Financial Performance
      • 8.2.6.3. Service Benchmarking
      • 8.2.6.4. Strategic Initiatives
    • 8.2.7. EUROAPI
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Financial Performance
      • 8.2.7.3. Service Benchmarking
      • 8.2.7.4. Strategic Initiatives
    • 8.2.8. Curia Global, Inc.
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Performance
      • 8.2.8.3. Service Benchmarking
      • 8.2.8.4. Strategic Initiatives
    • 8.2.9. CordenPharm
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Financial Performance
      • 8.2.9.3. Service Benchmarking
      • 8.2.9.4. Strategic Initiatives
    • 8.2.10. Sylentis, S.A.
      • 8.2.10.1. Company Overview
      • 8.2.10.2. Financial Performance
      • 8.2.10.3. Service Benchmarking
      • 8.2.10.4. Strategic Initiatives